This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BioDelivery Sciences Appoints Thomas W. D'Alonzo To Board Of Directors

Stocks in this article: BDSI

RALEIGH, N.C., April 29, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the appointment of Thomas W. D'Alonzo to the company's Board of Directors.  Mr. D'Alonzo previously served on the BDSI Board of Directors from August 2006 through June 2008.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"We are very pleased to once again have Tom D'Alonzo as a member of our Board of Directors," said Dr. Frank E. O'Donnell, Jr., Executive Chairman of BDSI.  "Tom's significant industry experience and leadership, which spans over more than 30 years in both large pharmaceutical and smaller biotechnology companies, will be a tremendous asset to BDSI." 

Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI added, "Tom's extensive business and commercial experience and expertise will be particularly important as we continue to explore our options for the commercialization of BUNAVAIL for the treatment of opioid dependence, which includes commercializing the product on our own.  We welcome Tom back and look forward to his contributions, which I am confident will assist BDSI in continuing to build value for patients and our stockholders."

Mr. D'Alonzo has held numerous high-level executive positions and board appointments within both large and specialty pharmaceutical companies.  Mr. D'Alonzo has been a member of the Board of Directors at Salix Pharmaceuticals since May 2000 and Chairman of the Board since June 2010.  Mr. D'Alonzo has previously served on the Board of Directors of Plexigen, Inc., DARA BioSciences, Inc. and Amarillo Biosciences, Inc.

Mr. D'Alonzo's extensive pharmaceutical industry background also includes a number of executive positions, including Chief Executive Officer at biotechnology companies DARA BioSciences, Inc. and GenVec, Inc. and President and Chief Operating Officer at Pharmaceutical Product Development (PPD), LLC, a global provider of discovery and development services to the pharmaceutical industry.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs